LTR Pharma has officially debuted on the Australian Securities Exchange (ASX) under ticker code LTP.
Our foremost priority is to execute a bioequivalence trial of SPONTAN® to support expedited regulatory approvals, and to market and sell SPONTAN in the United States and Australia, first.
We have a highly experienced team of pharmaceutical developers and commercialisation experts driving this program forward – and valued investors backing us too.
Successful phase I human proof of concept study now complete. SPONTAN® has shown to be six times faster than oral PDE5 inhibitors.
On track to register the first PDE5 inhibitor nasal spray, in a market estimated to reach US$6.0B in 2028.
Progressing to bioequivalence study, with expedited regulatory filings in the United States and Australia within 1-2 years.
View our Shareholder Communications summary here
View our Corporate Directory here
LTR Pharma has received ethics approval for a clinical study of SPONTAN® in pulmonary arterial hypertension (PAH). PAH represents a significant global therapeutics market, estimated at
LTR Pharma Limited (ASX:LTP) has announced that more than 2,000 bottles of SPONTAN®, our rapid-onset intranasal vardenafil spray, have been dispensed in Australia under the
LTR Pharma (ASX: LTP) has confirmed the first patient-specific ROXUS® prescriptions received through Mavrox, Shed’s men’s health telehealth platform, have now been fulfilled in the